New York Times (May 31)
China’s biotechnology sector passed a milestone. This year’s prestigious meeting of the American Society of Clinical Oncology (ASCO) features “a presentation of a clinical trial conducted only in China.” Typically, the headliners have “featured drug trials that were run mainly at American and European hospitals.” This milestone “reflects the dizzying growth of China’s biotechnology sector. In just a few years, it has transformed from a sleepy industry into a juggernaut rapidly inventing and testing cutting-edge medicines.”
Tags: ASCO, Biotechnology, China, Clinical trial, Cutting-edge medicines, Drug trials, Europe, Growth, Headliners, Inventing, Juggernaut, Milestone, Oncology, Prestigious, Testing, U.S.
Wall Street Journal (September 14)
“For Monsanto owners, selling to Bayer provides a premium of 44%.” With relatively little overlap between the companies, antitrust issues should be less likely to threaten the merger. Moreover, “the deal seems to make strategic sense, as Bayer combines its pesticides franchise with a leader in seeds and biotechnology. Bayer is also known for health care, which will generate about half of the combined company’s sales. Crop sciences will contribute roughly the other half.”
Tags: Antitrust, Bayer, Biotechnology, Crop sciences, Health care, Merger, Monsanto, Overlap, Pesticides, Premium, Seeds
